×
About 1,733 results

ALLMedicine™ Fibrosarcoma Center

Research & Reviews  657 results

Primitive Myxoid Mesenchymal Tumor of Infancy With Fatal Hemorrhage In Utero: A Case Re...
https://doi.org/10.1097/MPH.0000000000002474 10.1136/bcr.09.2011.4851
Journal of Pediatric Hematology/oncology; Haga M, Motojima Y et. al.

May 11th, 2022 - Primitive myxoid mesenchymal tumor of infancy (PMMTI) is a rare soft tissue sarcoma in childhood. We present the case of a newborn male who experienced a severe hemorrhage in utero from the tumor on the scalp. He died at the age of 24 hours owing ...

ZFP64::NCOA3 gene fusion defines a novel subset of spindle cell rhabdomyosarcoma.
https://doi.org/10.1002/gcc.23052
Genes, Chromosomes & Cancer; Han R, Dermawan JK et. al.

May 7th, 2022 - Spindle cell rhabdomyosarcoma represents a rare neoplasm characterized by monomorphic spindle cells with a fascicular architecture and variable skeletal muscle differentiation. Following incidental identification of a ZFP64::NCOA3 gene fusion in a...

Combinations of anti-GITR antibody and CD28 superagonist ameliorated dextran sodium sul...
https://doi.org/10.1093/cei/uxac039
Clinical and Experimental Immunology; Ma K, Que W et. al.

May 6th, 2022 - Ulcerative colitis (UC) is one of the two main forms of inflammatory bowel disease (IBD) and is an idiopathic, chronic inflammatory disease of the colonic mucosa with an unclear etiology. Interleukin (IL)-10 has been reported to play a crucial rol...

Imaging characteristics of infantile fibrosarcoma.
https://doi.org/10.1016/j.crad.2022.03.023
Clinical Radiology; Eleti S, Meshaka R et. al.

May 4th, 2022 - To highlight the imaging findings in a case series of histologically confirmed infantile fibrosarcoma (IF) and identify any features specific to this entity. Retrospective identification was undertaken of patients with histologically confirmed IF ...

BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may af...
https://doi.org/10.1002/gcc.23040
Genes, Chromosomes & Cancer; Oh KY, Kim JH et. al.

Mar 31st, 2022 - Although several types of odontogenic tumors share the same mutations in MAPK pathway genes, their effects on MAPK activation remain unclarified. This study aimed to evaluate the associations between these mutations and ERK phosphorylation in amel...

see more →

Guidelines  1 results

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903261
Current Oncology (Toronto, Ont.); Perreault S, Chami R et. al.

Jan 14th, 2021 - Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and cons...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  5 results

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
https://clinicaltrials.gov/ct2/show/NCT03092323

Mar 28th, 2022 - This is a multicenter, randomized phase II trial with an initial safety run-in to test the safety and efficacy of neoadjuvant pembrolizumab with image-guided radiotherapy and adjuvant pembrolizumab compared to radiation therapy alone in patients w...

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01989598

Mar 2nd, 2022 - PRIMARY OBJECTIVES: I. To evaluate the antitumor activity of trametinib determined by overall response rate (ORR) in patients that are stratified into groups based on: biomarker positive (neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS], v-...

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
https://clinicaltrials.gov/ct2/show/NCT03874026

Sep 2nd, 2021 - Patients' selection thorough the identification of predictive factors still represent a challenge in metastatic colorectal cancer (mCRC). Cetuximab (Erbitux®), a chimeric monoclonal antibody binding to the Epidermal Growth Factor Receptor (EGFR), ...

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
https://clinicaltrials.gov/ct2/show/NCT04045691

Jan 19th, 2021 - BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapid...

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
https://clinicaltrials.gov/ct2/show/NCT00503295

Oct 2nd, 2014 - Sarcomas are uncommon mesenchymal malignancies that encompass a variety of tumors of soft tissue or bone. Included in this study are patients with osteosarcoma, Ewing sarcoma family tumors, malignant fibrous histiocytoma, synovial sarcoma, leiomyo...

see more →

News  24 results

Clinical Management of NTRK+ Advanced NSCLC
https://www.onclive.com/view/clinical-management-of-ntrk-advanced-nsclc

Oct 12th, 2021 - Ben Levy, MD: There are now 2 TRK [tyrosine receptor kinase] inhibitors that are active, proven and FDA approved for TRK fusion-positive lung cancer. The first is larotrectinib. This was initially published in the New England Journal of Medicine l...

NTRK- and RET-Targeted Agents Reshape Solid Tumor Landscape
https://www.onclive.com/view/ntrk-and-ret-targeted-agents-reshape-solid-tumor-landscape

Aug 5th, 2021 - Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge. Two classes of precision agents that have recently had drugs come onto the mark...

Larotrectinib Elicits Robust Responses in TRK Fusion Cancer
https://www.onclive.com/view/larotrectinib-elicits-robust-responses-in-trk-fusion-cancer

Jun 5th, 2021 - The highly selective, central nervous system (CNS)-active TRK inhibitor larotrectinib (Vitrakvi) yielded promising response rates in patients with TRK fusion cancer, including in those with CNS metastases at baseline, according to the results of a...

Genomic Era Reaches Pediatric Oncology
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

FDA Grants Larotrectinib Priority Review for NTRK+ Cancers
https://www.onclive.com/view/fda-grants-larotrectinib-priority-review-for-ntrk-cancers

Dec 4th, 2020 - Anna F. Farago, MD, PhD The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according...

see more →

Patient Education  4 results see all →